-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Metastatic castration-resistant prostate cancer (mCRPC) disproportionately affects the elderly
This study aims to compare the clinical efficacy and tolerability of AA and enzalutamide in mCRPC patients 80 years and older
This is a retrospective propensity-weighted comparative cohort study that recruited mCRPC patients over 80 years of age who were treated with first-line AA or enzalutamide
A) The time from the start of treatment to the progression of PSA; B) The time before any progression; C) The time before treatment failure; D) Overall survival rate
A) The time from the start of treatment to the progression of PSA; B) The time before any progression; C) The time before treatment failure; D) Overall survival rateA total of 278 patients were enrolled, of which 153 were treated with AA and 125 were treated with enzalutamide
Enzalutamide treatment is associated with a higher PSA remission rate and TTP , but not related to TTPP.
Enzalutamide is associated with a higher PSA response rate and longer time to progression Enzalutamide is associated with a higher PSA response rate and longer time to progression
Original source:
Original source:Soleimani Maryam,Zou Kevin,Sunderland Katherine et al.
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study
in this message